markedly amplify clot lysis. The combination of RWR and a plasminogen activator increases the potency (for 50% lysis) of streptokinase, urokinase, and t-PA by 20-80-fold yet does not appear to increase nonspecific consumption of fibrinogen in vitro.3
T hrombolytic therapy for myocardial infarction has been delayed or underused because of concern about hemorrhagic complications. Indeed, at the doses routinely administered, all plasminogen activators can cause systemic fibrinolysis with degradation of clotting factors such as fibrinogen.' This complication has prompted a search for novel thrombolytic strategies that can increase clot lysis without causing a systemic lytic state. One recently reported strategy23 is to use a monoclonal antibody (MAb) that inactivates both plasma and clot (fibrin)-bound human a2-antiplasmin, the chief inhibitor of clot lysis.4 When added to clotted plasma in vitro this antibody, RWR, facilitates the "spontaneous" clot lysis induced by endogenous plasminogen activator. When added to clots in combination with tissue-type plasminogen activator (t-PA), MAb RWR interacts synergistically with the t-PA to markedly amplify clot lysis. The combination of RWR and a plasminogen activator increases the potency (for 50% lysis) of streptokinase, urokinase, and t-PA by 20-80-fold yet does not appear to increase nonspecific consumption of fibrinogen in vitro. 3 The following in vivo experiments were performed to test whether selective inhibition of fibrin-crosslinked a2-antiplasmin is an effective thrombolytic strategy. We used the rabbit jugular vein thrombolytic model originally described by Collen et a15 as it has been modified by our laboratory. 6 The results suggest that specific inhibition of clot-bound a2-antiplasmin can significantly increase the rate of thrombolysis without increasing the consumption of clotting factors such as fibrinogen.
Methods Proteins
t-PA with a specific activity of 580,000 IU/mg was purchased from Genentech, South San Francisco, California. MAb RWR and MAb 40-160 (an antidigoxin, control antibody) were raised as described.3'7 Both MAbs were purified from ascites by ammonium sulfate precipitation followed by ion exchange chromatography on DEAE-Affigel Blue, Bio-Rad, Richmond, California. The concentration of MAb RWR was determined by a competition radioimmunoassay similar to that described by Mariani et al. 8 The concentration of antidigoxin MAb 40-160 was measured by spectrophotometry with an extinction coefficient (1% solution, 1 cm path length) of 1.43.
Reed et al a2-Antiplasmin and Thrombolysis 165 a2-Antiplasmin was purified from human and rabbit plasma by Wiman's method.9
In Vitro Experiments Antibody-binding assays were performed to study the binding of MAb RWR to human and rabbit a2-antiplasmin. Wells of a microtiter plate were coated with 25 4L of a 10 ,ug/mL solution of human or rabbit a2-antiplasmin for 1 hour at room temperature. The wells were then rinsed and treated with 100 ,uL of a 1% solution of bovine serum albumin (RIA grade) in phosphate-buffered saline containing 0.02% azide (PBSA) to saturate any nonspecific protein-binding sites. The plates were washed again and tapped dry. Dilutions of MAb RWR (from mature hybridoma culture supernatant) were added in triplicate to wells containing human or rabbit a2-antiplasmin or a control (bovine serum albumin alone). After incubation for 1 hour, the wells were washed eight times and tapped dry. Then, 25 ,L (about 50,000 cpm) of radioiodinated goat-antimouse F(ab')2 antibody (Cappel Laboratories, West Chester, Pennsylvania) was added to each well and allowed to incubate for 1 hour. Subsequently, the unbound radioactive antibody was aspirated, and the plates were washed and dried. The wells were cut out and gamma-counted to determine the amount of bound antibody.
In vitro clot lysis assays were performed with fresh-frozen rabbit plasma collected on citrate and pooled from four normal rabbits. Collen et al. 5 The experiments were performed as previously described by our laboratory,6 with the following modifications. After the 125I-labeled fibrinogen, human plasma, and red blood cells had clotted in the jugular vein for 30 minutes, t-PA or placebo (saline) was administered by a constant infusion pump through the contralateral, marginal ear vein for 1 hour. In rabbits that received MAb RWR or the control MAb (antidigoxin 40-1607), the antibody was given as a single bolus (1.4 mg/kg, 1-2 ml) immediately before the infusion of t-PA or placebo. Two hours after the t-PA or placebo infusion had been terminated, the jugular vein was ligated, excised, and gamma-counted. The percentage lysis was computed from the ratio of the original vein cpm to the final vein cpm as described.5,6 Blood samples (1 ml) were collected before the agents were administered and at the end of the study. The samples were collected on sodium citrate (0.38% final) and P-PACK (10.4 ,ug/ml final) (Sigma Chemical, St. Louis, Missouri), centrifuged immediately, and frozen at -80°C until assay for fibrinogen and a2-antiplasmin.
All in vivo experiments were performed by one technician who was blinded to the dose of antibody or t-PA. Of the 40 thrombolysis experiments completed according to this protocol, 13 were rejected: eight because of unsatisfactory vein and clot preparation, four because of improper infusion of agent, and one because of excessive movement due to inadequate sedation. Results from the remaining 27 experiments were analyzed and are reported in detail. At the completion of this series, two additional (control) experiments were performed in which the rabbits were given an inert, antidigoxin antibody (MAb 40-160) as a placebo.
Values are given as mean±SEM. A two-sample t test was used to compare the means of different groups.
Results
Because MAb RWR was selected for its ability to bind to human a2-antiplasmin, a radioimmunoassay was performed to test its ability to bind to rabbit a2-antiplasmin. Figure 1 compares thrombolysis by the rabbit's endogenous plasminogen activator.
To determine whether clot-specific inhibition of a2-antiplasmin affected the fibrin selectivity of t-PA, we measured the residual fibrinogen levels for RWR and t-PA in combination and those for t-PA alone ( Figure 5A and B) . Fibrinogen levels remained substantially unchanged as a function of clot lysis for both combination and single-agent regimens. In addition, we measured antiplasmin levels for the two regimens ( Figure 6) . Although the antiplasmin level for rabbits receiving t-PA without MAb RWR appeared slightly less at the 26% lysis point, this difference was the result of one outlying value. Thus, there was no apparent decrease in a2-antiplasmin levels in rabbits that received the a2-antiplasmin inhibitor, confirming our previous results (Figure 2 ) that MAb RWR has no measurable inhibitory effect on rabbit a2-antiplasmin. In vivo, a2-antiplasmin is present in two forms: circulating free in the plasma and covalently crosslinked to the a chain of fibrin. Both forms inhibit fibrinolysis,13 although it has been hypothesized that the role of free a2-antiplasmin is largely to inhibit circulating plasmin and prevent a systemic lytic state.14,15 Sakata and Aoki4 have shown that fibrinbound a2-antiplasmin is a critical inhibitor of clot lysis. Their experiments demonstrate that clots from a2-antiplasmin-deficient patients undergo spontaneous lysis even when those clots are suspended in plasma containing normal levels of free a2-antiplasmin. We have extended their findings by demonstrating that an inhibitor of clot-bound antiplasmin can augment thrombolysis even when it is administered after clot formation to an animal whose circulating levels of free a2-antiplasmin are normal.
In rabbits, t-PA is the most potent and clot-specific thrombolytic agent.5 Thus, the improved lytic potency of t-PA by MAb RWR was a rigorous test of the feasibility of a clot-specific inhibitor of a2-antiplasmin. Furthermore, these experiments demonstrated that the combination of t-PA and MAb RWR did not increase fibrinogen consumption over that obtained with equipotent doses of t-PA alone. As such, clotspecific inhibition of a2-antiplasmin enhances the potency of t-PA and preserves its fibrin selectivity. In the case of an agent such as urokinase, which is not selective for fibrin, it is likely that a clot-specific inhibitor of a2-antiplasmin would cause a similar, or more pronounced, enhancement in potency and lead to less fibrinogen consumption as well.
Like all in vivo models, these experiments are imperfect approximations to a human thrombolytic situation. Yet 
